ANDA 205927

ANDA APPROVAL

Mylan Pharmaceuticals Inc.
781 Chestnut Ridge Rd
P.O. Box 4310
Morgantown, WV 26504
Attention: Shane Shupe
   Director, Regulatory Affairs

Dear Sir:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on July 10, 2013, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Prasugrel Tablets, 5 mg and 10 mg.

Reference is also made to the tentative approval letter issued by this office on January 8, 2016, and to your amendments received on March 2, April 4, and April 28, 2017.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the ANDA is approved, effective on the date of this letter. The Office of Bioequivalence has determined your Prasugrel Tablets, 5 mg and 10 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Effient Tablets, 5 mg and 10 mg, of Eli Lilly and Company (Lilly). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

The RLD upon which you have based your ANDA, Lilly’s Effient Tablets, 5 mg and 10 mg, is subject to periods of patent protection. The following patents and expiration dates (with pediatric exclusivity added) are currently listed in the Agency’s publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”):

<table>
<thead>
<tr>
<th>U.S. Patent Number</th>
<th>Expiration Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>5,288,726 (the ’726 patent)</td>
<td>October 14, 2017</td>
</tr>
<tr>
<td>8,404,703 (the ’703 patent)</td>
<td>July 2, 2023</td>
</tr>
<tr>
<td>8,569,325 (the ’325 patent)</td>
<td>July 2, 2023</td>
</tr>
</tbody>
</table>
Your ANDA contains paragraph IV certifications to each of the patents\(^1\) under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Prasugrel Tablets, 5 mg and 10 mg, under this ANDA. You have notified the Agency that Mylan Pharmaceuticals Inc. (Mylan) complied with the requirements of section 505(j)(2)(B) of the FD&C Act and that litigation was initiated within the statutory 45-day period against Mylan for infringement of the '726, '703 and '325 patents in the United States District Court for the Southern District of Indiana, Indianapolis Division [Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Daiichi Sankyo, Inc. and Ube Industries Ltd. v. Accord Healthcare, Inc. USA, et. al., Civil Action No. 1:14-cv-00389-LJM-TAB]. You have also notified the agency that the case has been dismissed. The RLD upon which you have based your ANDA, Lilly’s Effient Tablets, 5 mg and 10 mg, is subject to a period of exclusivity. As noted in the Orange Book, the pediatric exclusivity attaching to U.S. Patent No. 5,288,726 (the ’726 patent), is scheduled to expire on October 14, 2017. You have provided a copy of a letter from Eli Lilly that waives the pediatric exclusivity period associated with the ’726 patent. The waiver is effective from June 28, 2017. This ANDA is, therefore, eligible for approval.

With respect to 180-day generic drug exclusivity, we note that Mylan was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Prasugrel Tablets, 5 mg and 10 mg. Therefore, with this approval, Mylan is eligible for 180 days of shared generic drug exclusivity for Prasugrel Tablets, 5 mg and 10 mg. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, will begin to run from the date of the commercial marketing by any first applicant, as identified in section 505(j)(5)(B)(iv). Please submit a correspondence to this ANDA informing the Agency of the date you begin commercial marketing.

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

**REPORTING REQUIREMENTS**

Post marketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling materials prior to publication or dissemination. Please note that these submissions are voluntary. To do so, submit, in triplicate, a cover letter requesting advisory comments, the

---

\(^1\) The Agency notes that the ‘325 patent was submitted to the Agency after submission of your ANDA. Litigation, if any, with respect to this patent would not create a statutory stay of approval.
proposed materials in draft or mock-up form with annotated references, and the package insert (PI), Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

You must also submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

ANNUAL FACILITY FEES

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1st of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical in content to the approved labeling (including the package insert, and any patient
package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf. The SPL will be accessible via publicly available labeling repositories.

The Electronic Common Technical Document (eCTD) is CDER’s standard format for electronic regulatory submissions. Beginning May 5, 2017, ANDAs must be submitted in eCTD format and beginning May 5, 2018, drug master files must be submitted in eCTD format. Submissions that do not adhere to the requirements stated in the eCTD Guidance will be subject to rejection. For more information please visit: www.fda.gov/ectd.

Sincerely yours,

{See appended electronic signature page}

For Heidi Lee, PharmD
Acting Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research